FDA accepts Topaz NDA

Created on 07.06.11

The US Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Topaz Pharmaceuticals...

The application is for the use of ivermectin topical cream as a treatment for head lice infestations in children and adults. Topaz CEO and President Robert Radie said the filing represented the Pennsylvania company's transition from the development phase towards commercialisation. More...

Join us on Twitter

Site Map   |    Privacy Policy   |   Terms & Conditions

© 2012-2013 pediculosis.com — all rights reserved